Dec 8th – Become 1 of 1,806,000 New “Musk Millionaires” [How To Guide]

Hey there, bargain hunter. When a FTSE 100 company announces a £2.24 billion acquisition and the shares go up about 4%, the market is telling you something. The question is whether it is telling you the deal is genuinely cheap, or merely that the alternative was worse.

Scoreboard

Informa agreed on Tuesday, October 6, 2026, to buy event and exhibition organiser Clarion from private equity firm Blackstone for £2.24bn, while announcing plans to separate its academic business, Taylor & Francis, to focus on the core B2B operation. The consideration will be paid in cash and funded through dedicated acquisition financing and the net proceeds of an equity placing and retail offer of around £940m, representing about 9% of Informa’s issued ordinary share capital. Shares opened higher on the news.

The Real Reason the Multiple Matters

Informa is marketing this deal at roughly 9x EBITDA. That figure gets the headlines. It is not the price being paid today.

The deal values Clarion at 11.1x 2027 expected EBITDA, or around 9x including the £50m run-rate cost synergies identified to date. Those synergies have not been delivered. They are a target, not a result. The real entry multiple, right now, before a single pound of costs has been cut, is 11.1x forward EBITDA on a business Blackstone bought for about £600m in 2017 and ran hard for nine years.

The acquisition is expected to generate £75 million in annual run-rate synergies by 2029, comprising the £50m of cost savings plus £25 million of additional operating profit from targeted revenue synergies by 2029. All of that sits three years out. Between now and then, Informa is carrying the full price tag.

What Clarion Actually Is

Founded in 1947, Clarion Events employs around 2,000 people in 12 countries around the globe. Across nine years of Blackstone ownership, the company was built aggressively through M&A and now consists of more than 100 B2B brands. The portfolio spans gaming industry events like ICE Barcelona, pop culture conventions, defence expos, and marine shows. Informa has outlined expectations to investors that Clarion will generate more than £575m in revenue for calendar year 2027.

Data That Matters

• Enterprise value: £2.24bn (about $2.96bn)
• Entry multiple: 11.1x 2027 expected EBITDA
• Post-synergy multiple (2029 target): ~9x
• Equity raise: approximately £940m through a placing and retail offer, roughly 9% of issued share capital
• Leverage at close: pro-forma net debt to EBITDA expected to remain below 3x at year-end 2026, falling to below 2.5x by year-end 2027
• EPS: mid-single-digit boost to 2027 adjusted diluted earnings per share, against a 2025 base of 49p
• Taylor & Francis revenue: approaching $1 billion annually, growing at approximately 4% a year

Is It Cheap?

At 11.1x forward EBITDA, Informa is not stealing Clarion. It is paying a full private equity exit price for a business that Blackstone spent nine years optimising. The 9x framing requires £75m of synergies that land in 2029, one-off delivery costs of about £50 million, and a Taylor & Francis separation that has no confirmed structure yet. Informa has launched a process to review all options, with outcomes due alongside the 2026 full-year results in March 2027. That is a lot of moving parts before the cheaper multiple becomes real.

Bull / Base / Bear

Bull: Informa executes its events playbook the way it has before. Clarion’s brands scale into the Middle East, where revenue opportunities include taking brands into new markets, particularly given Clarion’s relatively limited Middle East footprint. Synergies arrive on schedule. Taylor & Francis fetches a strong price and reduces leverage faster than guided.

Base: Synergies slip by a year. The combined B2B events business grows at the guided 7%, leverage tracks to 2.5x by end of 2027 as promised, and EPS is modestly accretive from 2027. Nothing breaks, but the multiple never compresses to 9x before 2030.

Bear: A recession hits corporate event budgets. A roughly 9%-dilutive equity raise at a depressed share price locks in permanent dilution. Taylor & Francis draws weak bids in a soft academic publishing market, leaving Informa with leverage above target and no clean exit from the asset.

Action Plan

Do not chase the post-announcement bounce. The equity raise means new shares are landing in the market. If you want exposure to Informa’s events consolidation, let the dilution settle and watch whether the placing price holds as a floor. A scale-in starting after the Clarion close in Q4 2026, with a second tranche once the Taylor & Francis outcome is known in March 2027, gives you two cleaner data points before committing full size.

Cheap Investor Checklist

• Does the actual deal multiple compress toward 9x within three years, or does it stall at 10x-plus?
• Is Informa’s leverage below 2.5x by December 2027 as guided?
• Do the £50m cost synergies arrive on the 2029 schedule, or get pushed?
• What does Taylor & Francis fetch? A sale above book value accelerates deleveraging.
• Does EPS accretion materialise in 2027 results, not just in guidance?
• Is the share buyback reinstated once leverage falls, signalling management confidence?
• Watch Clarion’s 2027 revenue: the £575m target needs to hold.

Bottom Line

If Informa delivers £75m of synergies by 2029 and separates Taylor & Francis cleanly, today’s 11.1x entry multiple becomes defensible in hindsight. If either leg slips, bargain hunters who paid full price at announcement will spend years waiting for the discount they were sold at the outset. The story is real. The cheap part has not arrived yet.